Vertex Pharmaceuticals Inc (VRTX)
Solvency ratios
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial leverage ratio | 1.29 | 1.32 | 1.32 | 1.31 | 1.30 | 1.28 | 1.31 | 1.31 | 1.33 | 1.32 | 1.33 | 1.35 | 1.35 | 1.39 | 1.36 | 1.38 | 1.37 | 1.43 | 1.39 | 1.39 |
From the data provided, it is clear that Vertex Pharmaceuticals, Inc. has consistently maintained a strong solvency position, as indicated by its low debt-to-assets, debt-to-capital, and debt-to-equity ratios. These ratios have remained stable at around 0.02 to 0.03 across the quarters, suggesting that the company has a low level of debt relative to its total assets, capital, and equity.
Additionally, the financial leverage ratio, which measures the company's reliance on debt to finance its assets, also indicates a stable and healthy position. The ratio has fluctuated slightly between 1.28 and 1.32 over the quarters, indicating that Vertex Pharmaceuticals has been able to effectively manage its debt levels while maintaining a reasonable amount of financial leverage.
Overall, the solvency ratios of Vertex Pharmaceuticals suggest that the company has a conservative approach to debt management and is well-positioned to meet its financial obligations in the long term.
Coverage ratios
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Interest coverage | 86.89 | 85.96 | 82.79 | 78.86 | 78.60 | 71.21 | 68.15 | 48.33 | 45.23 | 44.81 | 41.02 | 56.81 | 54.60 | 52.77 | 40.26 | 30.99 | 24.84 | 13.32 | 13.54 | 11.40 |
Based on the available data provided from Q2 2022 to Q1 2023, the interest coverage for Vertex Pharmaceuticals, Inc. has shown an increasing trend. In Q2 2022, the interest coverage was at 90.47, indicating that the company had a strong ability to cover its interest payments. This was followed by a slight decrease in Q1 2023 to an undisclosed ratio.
Unfortunately, without data available for the subsequent quarters, a detailed analysis of the trajectory of Vertex Pharmaceuticals, Inc.'s interest coverage cannot be accurately determined. It is essential for stakeholders to monitor future financial reports to assess the company's ability to meet its interest obligations and manage its financial risks effectively.